{"entity":{"id":"nct03603795","kind":"trial","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","aka":[],"tldr":"A phase 2 trial of Eltrombopag in Acute myeloid leukaemia, run by French Innovative Leukemia Organisation, active and no longer recruiting.","summary":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy is a phase 2 interventional study registered as NCT03603795 by French Innovative Leukemia Organisation, with 110 participants planned, started 2018-10-11 and due to reach its primary completion in 2022-06-15. Interventions recorded: Eltrombopag, Placebo. Conditions recorded: Acute Myeloid Leukemia.\n\nLinked to the drug Eltrombopag because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03603795","url":"https://clinicaltrials.gov/study/NCT03603795"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["eltrombopag"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03603795","phase":"2","setting":"A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","sponsor":"French Innovative Leukemia Organisation","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03603795/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/"}]}}